USPTO serial 79448458
Reviewed by CopyMark Law Group
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Camille M. Miller
Camille M. Miller Cozen O'Connor1650 Market Street, Suite 2800Philadelphia, PA 19103United States| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for the treatment of pain management, infectious diseases, central nervous system disorders, namely, epilepsy, anxiety, and depression, hypertension, cholesterol management, heart disease, acid reflex, ulcers and irritable bowel syndrome, diabetes, thyroid disorders, side effects of cancer treatments, bone diseases, allergic reactions, shock, malignant diseases, and kidney disorders; pharmaceutical preparations for the treatment of pain management, infectious diseases, central nervous system disorders, namely, epilepsy, anxiety, and depression, hypertension, cholesterol management, heart disease, acid reflex, ulcers and irritable bowel syndrome, diabetes, thyroid disorders, side effects of cancer treatments, bone diseases, allergic reactions, shock, malignant diseases, and kidney disorders; ready-to-administer injectable pharmaceutical preparations for the treatment of allergic reactions, hypotension, shock, malignant diseases, and kidney disorders, and to provide and reverse muscle relaxation to be used in patient care facilities, namely, hospitals, acute care facilities, and long term care facilities; radio frequency identification tagged pharmaceutical products for the treatment of cardiovascular, central nervous system, infectious, metabolic, respiratory, gastrointestinal, inflammatory, oncologic, and pain related conditions, namely, sympathomimetic agents, diagnostic agents, anticoagulants, thrombin inhibitors, anesthetics, analgesics, endocrine metabolics, antibacterial agents, antibiotics, skeletal muscle relaxants, injectable estrogens, diuretic agents, psychiatries, antivirals, thyroid agents, corticosteroids, antifungals, immunosuppressive agents, parasympathomimetic agents, vasoconstrictors, oxytocic agents, antiemetics, vasopressin antagonists, vasodilators, vasopressors, anti-epileptics, anticonvulsants, cholinesterase inhibitors, and antimuscarinic agents; pharmaceutical preparations for the treatment of cardiovascular, central nervous system, infectious, metabolic, respiratory, gastrointestinal, inflammatory, oncologic, and pain related conditions; pharmaceutical and medical preparations in connection with critical care, critical testing, maternal health, anesthesia, diseases, kidney disorders, cellulite, skin care, dermatological use, folds, scars, and body contouring and for rejuvenating to-administer injectable pharmaceutical preparations for the treatment of allergic reactions, hypotension, shock, malignant diseases, and kidney disorders, and to provide and reverse muscle relaxation to be used in patient care facilities, namely, hospitals, acute care facilities, and long term care facilities and in doctor's offices; pharmaceutical preparations, namely, analgesics and pain management preparations, preparations for the treatment of cancers, preparations for the treatment of urological diseases and disorders, preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, hormone replacement therapy preparations; drug substances, namely, enzymes for medical purposes; pharmaceutical preparations for the treatment of cellulite; pharmaceutical preparations for skin care; medicated skin care gels and mineral supplements; food supplements; radio frequency identification tagged pharmaceutical products, namely, sympathomimetic agents, diagnostic agents, anticoagulants, thrombin inhibitors, anesthetics, analgesics, endocrine metabolics, antibacterial agents, antibiotics, skeletal muscle relaxants, injectable estrogens, antifungals, immunosuppressive agents, parasympathomimetic agents, vasoconstrictors, oxytocic agents, antiemetics, vasopressin antagonists, vasodilators, vasopressors, anti-epileptics, anticonvulsants, cholinesterase inhibitors, and antimuscarinic agents for the treatment of urinary urgency, breathing, saliva and secretion, gut motility, and heart rate, endocrinology, orthopedics, and urology; pharmaceuticals preparations, namely, a blood clotting aid and delivery system for human use; prefilled syringe containing injectable pharmaceuticals for manual injection for the treatment of pain management, infectious diseases, central nervous system disorders, namely, epilepsy, anxiety, and depression, hypertension, cholesterol management, heart disease, acid reflex, ulcers and irritable bowel syndrome, diabetes, thyroid disorders, side effects of cancer treatments, bone diseases, allergic reactions, shock, malignant diseases, and kidney disorders | ACTIVE | — |
| 035 | Healthcare management services, namely, providing administrative support services to physicians and healthcare providers who prescribe pharmaceutical preparations; outsourcing services in the nature of arranging service contracts or others in the field of pharmaceuticals; business administration of patient reimbursement programs for pharmaceuticals; business administration of patient assistance programs that provide pharmaceuticals to help patients with insufficient resources get treatment at little or no cost to the patient | ACTIVE | — |
| 036 | Providing health insurance information about health insurance benefits to patients; financial administration of patient reimbursement programs for pharmaceuticals; financial administration of patient assistance programs that provide pharmaceuticals to help patients with insufficient resources get treatment at little or no cost to the patient; financial assistance programs that provide pharmaceuticals to help patients with insufficient resources to get treatment at little or no cost to the patient | ACTIVE | — |
| 040 | Manufacture of pharmaceutical products to the order and specification of others; providing technical information in the field of pharmaceutical manufacturing | ACTIVE | — |
| 042 | Development of pharmaceutical preparations and medicines; pharmaceutical drug development services; pharmaceutical research and development; pharmaceutical research services; medical research in the fields of chemicals and pharmaceuticals; scientific research and testing services in the fields of chemicals and pharmaceuticals; research and development of new products for others in the fields of chemicals and pharmaceuticals; development of pharmaceutical products to specifications of others; research and development of pharmaceutical products for others. | ACTIVE | — |
| 044 | Providing medical information and medical information via a website on the subjects of pharmaceutical preparations and medicines, medical devices and techniques; providing medical information and online medical and healthcare information to healthcare professionals and patients; providing medical information via a website; providing medication counseling information, namely, advice and data on the subjects of pharmaceutical preparations and medicine; providing medical information on the subjects of aesthetic solutions to help patents feel better about their bodies | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 30, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 30, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 18, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 20, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 20, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 20, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 20, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 5, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 5, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 10, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 9, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 1, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 23, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 23, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 23, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |